Dr. Reginald James Baldwin, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 590 Harbor St, Morro Bay, CA 93442 Phone: 805-772-1269 Fax: 805-772-2172 |
Dr. Leia Michelle Dumlao Ballesteros, OD Optometrist Medicare: Medicare Enrolled Practice Location: 590 Harbor St, Morro Bay, CA 93442 Phone: 805-772-1269 Fax: 805-772-2172 |
Morro Bay Optometry Optometrist Medicare: Not Enrolled in Medicare Practice Location: 590 Harbor St, Morro Bay, CA 93442 Phone: 805-772-1269 |
Tiffany Smart, O.d. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 590 Harbor St, Morro Bay, CA 93442 Phone: 805-772-1269 Fax: 805-772-2172 |
Dr. Nadine L Norris, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 800 Quintana Rd, Suite 1d, Morro Bay, CA 93442 Phone: 805-772-6166 Fax: 805-772-5128 |
Dr. Tiffany Tyler Smart, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 590 Harbor St, Morro Bay, CA 93442 Phone: 805-772-1269 Fax: 805-772-2172 |
Sally Elizabeth Melendez, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 590 Harbor St, Morro Bay, CA 93442 Phone: 805-772-1269 Fax: 805-772-2172 |
News Archive
Why are fat deposits more likely to occur after tears of the shoulder's rotator cuff, compared to other types of muscle injuries? An increased propensity of stem cells within with rotator cuff muscles to develop into fat cells may explain the difference, reports a study in the February 6, 2019 issue of The Journal of Bone & Joint Surgery.
Directly activating a gene important to exciting our excitatory neurons and associated with major depression may help turn around classic symptoms like social isolation and loss of interest, at least for males, scientists report.
The United Nations Foundation (UN Foundation) announced today that it has received a US$139 million contribution from the GAVI Alliance to support the worldwide effort by the Measles Initiative to reduce measles deaths by 90 percent by 2010.
Shield Therapeutics, an independent specialty pharmaceutical company focused on the development of mineral-derived hospital pharmaceuticals, today announces that it has filed an investigational new drug application with the US Food and Drug Administration to initiate a Phase 3 pivotal study of ST10, its novel oral iron-replacement therapy, for the treatment of iron deficiency anaemia in pre-dialysis patients with chronic kidney disease.
› Verified 7 days ago